Bipolar disorder adherence project
| ISRCTN | ISRCTN56622673 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN56622673 |
| Integrated Research Application System (IRAS) | 177031 |
| Protocol serial number | 319169, IRAS 177031 |
| Sponsor | Mednet Consult Ltd |
| Funder | Small Business Research Initiative (UK) |
- Submission date
- 27/01/2015
- Registration date
- 10/02/2015
- Last edited
- 02/09/2020
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Mental and Behavioural Disorders
Plain English summary of protocol
Background and study aims
People with bipolar disorder will have periods of depression, during which they will feel very low and lethargic, and mania, during which they will feel very high and overactive. Biodose Connect™ is a medicines adherence service that can be used to provide medications for patients with bipolar disorder and co-medications for other medical conditions. The aim in this study is to offer patients with bipolar disorder, who have or have had issues with medication adherence, medication adherence support with web-based psychoeducation module on relapse prevention and Biodose Connect™.
Who can participate?
Adults with bipolar disorder
What does the study involve?
The community pharmacist will dispense the patient’s medication into the Biodose Connect™ system and the tray will be delivered to the patient’s chosen location. The community psychiatric nurse (CPN) will assign the psychoeducation module to the patient. A link will be sent by email to the patient with details of how to access the module. The patient will complete the online interactive module and take their medication as instructed. The Biodose Connect™ system will trigger a short message service text reminder to the patient if they have not taken their medication in the timeframe. It will also alert the CPN that the patient has not taken his or her medication. At the study endpoint, the patient and patient’s CPN will be required to complete an assessment to evaluate the programme.
What are the possible benefits and risks of participating?
Benefits and risks not provided at time of registration.
Where is the study run from?
White Abbey Hospital (UK)
When is the study starting and how long is it expected to run for?
From January 2015 to July 2015
Who is funding the study?
Small Business Research Initiative (UK)
Who is the main contact?
Miss Ayse Ibrahim
Contact information
Public
Mednet
40 Otley Road
Leeds
LS6 2AL
United Kingdom
 ORCID ID |
0000-0002-1610-626X |
|---|
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Open-label single-centre pilot study |
| Secondary study design | Non randomised study |
| Scientific title | Supporting medicines adherence in bipolar disorder through the use of psychoeducation and Biodose Connect™ |
| Study objectives | To demonstrate the value of an adherence support programme through satisfaction and clinical utility scores from patients and health-care professionals |
| Ethics approval(s) | Approved 22/04/2015, Yorkshire & The Humber - Leeds West Research Ethics Committee, REC ref: 15/YH/0118 |
| Health condition(s) or problem(s) studied | Bipolar disorder, currently in remission |
| Intervention | 1. Support will be provided as a medication internet-based psychoeducation module on relapse prevention and Biodose Connect™, which is an advanced medication and adherence management system using state-of-the-art technologies. 2. The patient will complete an education module on relapse prevention, designed to increase their knowledge of their disorder and enable them to create their own individual profile to recognise early signs and triggers of a relapse. 3. The patient's medication will be given in the Biodose Connect™ system and the patient will receive reminder texts if medication is not taken in the allocated timeframe. |
| Intervention type | Mixed |
| Primary outcome measure(s) |
Patient and health-care professional satisfaction scores will be captured with a satisfaction survey including rating scales and net promoter score at the end of the study (3 months after the start of study). |
| Key secondary outcome measure(s) |
Changes in adherence scores from study baseline to end of the study (3 months after the start of study) will be measured with an adherence assessment tool, which includes the Medication Adherence Rating Scale score and the Clinical Global Impression score. |
| Completion date | 05/07/2015 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | All |
| Target sample size at registration | 12 |
| Key inclusion criteria | 1. International Statistical Classification of Diseases and Related Health Problems diagnosis: F31.7 bipolar disorder, currently in remission 2. Taking medication for bipolar disorder 3. Will be treated by Northern Health and Social Care Trust (UK) 4. Medication Adherence Rating Scale score of 6 or less 5. Clinical Global Impression score of 3 or less (mildly ill) 6. Home access to the internet via a laptop or desktop computer 7. Informed consent and registration forms 8. Co-medications and liquid medications can be administered via Biodose Connect™ 9. Age 18–64 years old |
| Key exclusion criteria | 1. Significant cognitive impairment 2. Taking medication that is identified by the Medicines and Healthcare Products Regulatory Agency (UK) as not suitable for blister/biodose packaging 3. Poor communication and/or reading skills |
| Date of first enrolment | 16/03/2015 |
| Date of final enrolment | 06/06/2015 |
Locations
Countries of recruitment
- United Kingdom
- Northern Ireland
Study participating centre
Doagh Road
Newtownabbey
County Antrim
BT37 9RH
United Kingdom
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not expected to be made available |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| HRA research summary | 28/06/2023 | No | No |
Editorial Notes
02/09/2020: No publications found. IRAS Project ID and ethics approval details added.
08/08/2017: No publications found in PubMed, verifying study status with principal investigator.
